Hot Stocks Of The Day (SFL, DYSL, PCX, ONXX, ITMN)

Ship Finance International Limited (NYSE:SFL) shares climbed 4.92% to $14.51 in the early hour after the company posted first quarter net income of $39 million, or $0.49 per share, from $30 million, or $0.38 a share, in the same quarter a year earlier. Analysts were expecting earnings of $0.40 per share on revenue of $116.1 million. The Company reported total U.S. GAAP operating revenues on a consolidated basis of $84.1 million, or $1.06 per share, in the first quarter of 2012.Additionally, the company raised its quarterly dividend by 30% to $0.39 per share. The dividend will be paid on or about June 28, 2012 to shareholders of record as of June 15, 2012. The ex-dividend date will be June 13, 2012.


Dynasil Corporation of America (NASDAQ:DYSL) shares soared 27.41% to $1.72 in the morning hour after the company announced that it has entered into a technology collaboration agreement with Mayo Clinic. The first project under the collaborative agreement will focus on the development of a therapeutic hypothermia core cooling technology designed to protect the brain during cardiac arrest and traumatic brain injury. Separately, Dynasil and Mayo Clinic are working together on a blood storage technology designed to extend the shelf life of blood products.

Patriot Coal Corporation (NYSE:PCX) shares declined 7.14% to $2.47 in the early hour.  The company said that its refinancing plans are continuing and also confirmed that it is working with private-equity firmBlackstone Group LP (BX) on the effort.The company had earlier this month announced that it enteredinto a commitment letter for a new revolving credit facility and new term loanfacility for a total of $625 million from Citigroup Global Markets, Inc.,Barclays Bank PLC and Natixis, New York Branch.


Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) shares gained 4% to $45.76 in the early hour after the company announced that Bayer HealthCare has submitted a New Drug Application or NDA to the U.S. Food and Drug Administration or FDA seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer or mCRC. Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales of regorafenib in oncology.

InterMune, Inc. (NASDAQ:ITMN) shares fell 1.69% to $9.93 in the early hour.  Canaccord Genuity restates a 'Buy' on InterMune but price target lowered from $24 to $15. The company had announced last week that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.  Vidara is part of an international specialty pharmaceutical group of companies with operations in Ireland and the United States.